ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Simvastatin

Also written as “simvastatin”, “ezetimibe (+) simvastatin” and “Fenofibrate/Simvastatin”.

Its studies are mostly in Hypercholesterolemia · Diabetes Mellitus, Type 2 · Hyperlipidemias · Cardiovascular Diseases · Hypertension, led by 11 companies.

Drug pageSimvastatin: every studyMany companies study it; this page follows only the 65 they lead. All 370 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 7, 200565 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organonits history only290 open or runningphase 4since Sep 7, 2005Sep 21, 2004none ahead
Abbottits history only80 open or runningphase 3since Mar 25, 2004Mar 25, 2004none ahead
Eli Lillyits history only60 open or runningphase 2since Apr 15, 2010Apr 15, 2010none ahead
GlaxoSmithKlineits history only60 open or runningphase 3since Oct 28, 2005Oct 28, 2005none ahead
Merck60 open or runningphase 3since May 24, 2007May 24, 2007none ahead
Pfizerits history only40 open or runningphase 4since Sep 8, 2005Sep 8, 2005none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Jul 21, 2010Jul 21, 2010none ahead
Biogenits history only10 open or runningphase 4since Jun 25, 2007Jun 25, 2007none ahead
Entero Therapeuticsits history only10 open or runningearly phase 1since Oct 3, 2016Oct 3, 2016none ahead
Medtronicits history only10 open or runningearly phase 1since Jul 21, 2008Jul 21, 2008none ahead

Also a collaborator on its studies: Immunogenics, Regeneron Pharmaceuticals, Celerion and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 24, 2007First study: phase 3 study in Primary HypercholesterolemiaFirst studyNCT00479388 · 1,216 enrolled
  2. Nov 29, 2007Phase 3 study in HyperlipidemiasNCT00566267 · 58 enrolled
  3. Jul 7, 20092 phase 1 studiesNCT00935259, NCT00943124
  4. Apr 13, 2011Phase 3 study in HypercholesterolemiaNCT01335997 · 1,139 enrolled
  5. Aug 31, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01678820 · 299 enrolled

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
AtorvastatinruleViatrisphase 4186
rosuvastatinruleAstraZenecaphase 4184
pitavastatinruleKowaphase 436

Studies

All 6 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01678820Diabetes Mellitus, Type 23TerminatedNov 1, 2013299
NCT01335997Hypercholesterolemia3TerminatedJan 1, 20121,139
NCT00943124Dyslipidemias1CompletedAug 2007220
NCT00935259Hypercholesterolemia1CompletedOct 200931
NCT00566267Hyperlipidemias3Completed58
NCT00479388Primary Hypercholesterolemia3CompletedJul 20081,216

How it is read

Names in the registry

  • “Simvastatin”, 44 entries
  • “simvastatin”, 14 entries
  • “ezetimibe (+) simvastatin”, 9 entries
  • “Fenofibrate/Simvastatin”, 5 entries
  • “Ezetimibe + Simvastatin”, 4 entries

Codes read as this program: MK0733.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.